Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer drug gets a shot in the arm: testing a new, easier injection method

NCT ID NCT05017012

Ongoing Knowledge-focused Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new way to give the cancer drug pembrolizumab—as an injection under the skin instead of into a vein. The main goal is to see how much of the drug gets into the bloodstream and to check its safety when given this way. It involves 72 people with advanced solid tumors to gather initial data on this new formulation.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Bradfordhill ( Site 0100)

    Santiago, Region M. de Santiago, 8420383, Chile

  • CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE ( Site 0051)

    Port Elizabeth, Eastern Cape, 6055, South Africa

  • Cancercare Rondebosch Oncology-Clinical trials ( Site 0055)

    Rondebosch, Western Cape, 7700, South Africa

  • Cape Town Oncology Trials ( Site 0050)

    Cape Town, Western Cape, 7570, South Africa

  • FALP-UIDO ( Site 0101)

    Santiago, Region M. de Santiago, 7500921, Chile

  • HOSPITAL CLÍNIC DE BARCELONA-Department of Medical Oncology ( Site 0043)

    Barcelona, Catalonia, 08036, Spain

  • HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON-ONCOLOGY ( Site 0040)

    Madrid, Madrid, Comunidad de, 28009, Spain

  • Hospital Universitario Virgen de la Victoria-Phase I Trials Unit ( Site 0042)

    Málaga, Andalusia, 29010, Spain

  • James Lind Centro de Investigación del Cáncer ( Site 0102)

    Temuco, Región de la Araucanía, 4800827, Chile

  • Kansai Medical University Hospital ( Site 0112)

    Hirakata, Osaka, 573-1191, Japan

  • LIFE GROENKLOOF-Mary Potter Cancer Centre ( Site 0052)

    Pretoria, Gauteng, 0181, South Africa

  • Magyar Honvedseg Egeszsegugyi Kozpont-Onkologiai Osztaly ( Site 0020)

    Budapest, 1062, Hungary

  • Medical Oncology Centre of Rosebank ( Site 0058)

    Johannesburg, Gauteng, 2196, South Africa

  • National Hospital Organization Kyushu Cancer Center ( Site 0114)

    Fukuoka, 811-1395, Japan

  • Országos Onkológiai Intézet-Urogenital Tumors Department and Clinical Pharmacology ( Site 0021)

    Budapest, Pest County, 1122, Hungary

  • Osaka International Cancer Institute ( Site 0113)

    Osaka, 541-8567, Japan

  • Saitama Prefectural Cancer Center ( Site 0110)

    Ina-machi, Saitama, 362-0806, Japan

  • Samsung Medical Center ( Site 0063)

    Seoul, 06351, South Korea

  • Sandton Oncology Medical Group (Pty) Ltd-Research ( Site 0053)

    Sandton, Gauteng, 2196, South Africa

  • Severance Hospital, Yonsei University Health System ( Site 0062)

    Seoul, 03722, South Korea

  • Shizuoka Cancer Center ( Site 0111)

    Nagaizumi-cho,Sunto-gun, Shizuoka, 411-8777, Japan

  • Steve Biko Academic Hospital-Medical Oncology ( Site 0057)

    Pretoria, Gauteng, 0001, South Africa

Conditions

Explore the condition pages connected to this study.

ADVANCED OR METASTATIC SOLID TUMORS